Factory 99% Erlotinib HCl Powder CAS 183319-69-9 Chemical Intermediate Anticancer Erlotinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A545
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Erlotinib HCl
• CAS: 183319-69-9
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 10g
• Function: Anticancer
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Erlotinib HCl
Appearance	White Powder
CAS NO.	183319-69-9
MF	C22H23N3O4HCl
Storage	Keep in a cool, dry, dark location

 

Erlotinib HCl, also known as Tarceva, is a chemical compound with the molecular formula C22H23N3O4HCl. It is a small-molecule inhibitor of the epidermal growthfactor receptor (EGFR) tyrosine kinase, primarily used in the treatment of certain types of cancer.

 

1. Cancer Treatment: Erlotinib HCl is prescribed for the treatment of non-small cell lung cancer (NSCLC) in patients whose tumors have specific EGFR mutations.
2. Adjuvant Therapy: It is also used as an adjuvant therapy in combination with gemcitabine for patients with locally advanced, unresectable pancreatic cancer.
3. Maintenance Therapy: Following platinum-based chemotherapy, Erlotinib HCl can be administered as maintenance therapy to prolong survival in NSCLC patients.

1. Inhibition of EGFR Signaling: By binding to the EGFR tyrosine kinase domain, Erlotinib HCl inhibits the phosphorylation and activation of EGFR, thereby blocking downstream signaling pathways that promote cell proliferation, survival, and migration.
2. Reduction of Tumor Growth: This inhibition leads to the reduction of tumor growth and the induction of apoptosis (programmed cell death) in EGFR-expressing cancer cells.
3. Improvement of Survival Rates: Clinical studies have shown that Erlotinib HCl can improve progression-free survival and overall survival rates in specific patient populations with EGFR-mutated NSCLC.